Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.

被引：5

作者：

Minchom, Anna Rachel

Girard, Nicolas

Bazhenova, Lyudmila

Ou, Sai-Hong Ignatius

Gadgeel, Shirish M.

Trigo, Jose

Viteri, Santiago

Backenroth, Daniel

Bhattacharya, Archan

Li, Tracy

Mahadevia, Parthiv

Bauml, Joshua

机构：

[1] Royal Marsden Inst Canc Res, Drug Dev Unit, Sutton, Surrey, England

[2] Inst Curie, Paris, France

[3] Univ Calif San Diego, San Diego, CA 92103 USA

[4] Univ Calif Irvine, Orange, CA 92668 USA

[5] Henry Ford Hlth Syst, Henry Ford Canc Inst, Detroit, MI USA

[6] IBIMA, Hosp Univ Virgen Victoria & Reg, Malaga, Spain

[7] Grp QuironSalud, Ctr Med Teknon, Inst Oncol Dr Rosell, Barcelona, Spain

[8] Janssen R&D, Raritan, NJ USA

[9] Janssen R&D, High Wycombe, PA, England

[10] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.9052

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9052

引用

页数：2

共 50 条

[1] Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy
Minchom, Anna
Viteri, Santiago
Bazhenova, Lyudmila
Gadgeel, Shirish M.
Ou, Sai-Hong Ignatius
Trigo, Jose
Bauml, Joshua M.
Backenroth, Daniel
Bhattacharya, Archan
Li, Tracy
Mahadevia, Parthiv
Girard, Nicolas
LUNG CANCER, 2022, 168 : 74 - 82
[2] Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer EGFR Exon 20 insertion mutations after platinum-based chemotherapy
Kim, Tae Min
Girard, Nicolas
Low, Grace Kah Mun
Zhuo, Jianmin
Yu, Dae Young
Yang, Yishen
Murota, Maiko
Lim, Cindy Thiow Koon
Kleinman, Nora J.
Cho, Byoung Chul
ACTA ONCOLOGICA, 2023, : 1689 - 1697
[3] Real-World Response and Outcomes in Patients With NSCLC With EGFR Exon 20 Insertion Mutations
Ou, Sai-Hong Ignatius
Lin, Huamao M.
Hong, Jin-Liern
Yin, Yu
Jin, Shu
Lin, Jianchang
Mehta, Minal
Nguyen, Danny
Neal, Joel W.
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (10):
[4] Real-World Treatment Patterns of Patients with EGFR Exon 20 Insertion-Mutated Advanced NSCLC Treated with Amivantamab or Mobocertinib after Platinum-Based Chemotherapy
Spira, Alexander
Waters, Dexter
Ran, Tao
Vadagam, Pratyusha
He, Jinghua
Vanderpoel, Julie
Donnelly, Anjali
Lin, Iris
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E32 - E32
[5] Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
Ou, Sai-Hong Ignatius
Lin, Huamao Mark
Hong, Jin-Liern
Yin, Yu
Jin, Shu
Lin, Jianchang
Mehta, Minal
Nguyen, Danny
Neal, Joel W.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[6] Approval for RYBREVANT® (Amivantamab) in Patients with advanced NSCLC and activating EGFR Exon 20 Insertion Mutations after Failure of platinum-based Therapy
不详
ACTA HAEMATOLOGICA, 2022, 145 (02) : 230 - 230
[7] Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China
Shen, L.
Hu, G.
Wang, Y.
Zhao, J.
Li, X.
Zhuo, J.
Low, G.
Lu, S.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S347 - S348
[8] Treatment comparison of amivantamab vs. real-world therapies among patients with NSCLC harboring EGFR Exon 20 insertion mutations: An external control analysis (ECA) using NTUH NSCLC dataset in Taiwan
Wu, J-y.
Zhuo, J.
Chen, E.
Wang, S-p.
Hsieh, J-f.
Shih, J-y.
ANNALS OF ONCOLOGY, 2024, 35
[9] Approval for RYBREVANT® (Amivantamab) in advanced NSCLC and activating EGFR Exon 20 Insertion Mutations after Failure of Platinum-based Therapy
Freye, Reimund
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (1-2) : 72 - 72
[10] Amivantamab-Vmjw: A Novel Treatment for Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation after Progression on Platinum-Based Chemotherapy
Shah, Vishal
McNatty, Andrea
Simpson, Lacey
Ofori, Henry
Raheem, Farah
BIOMEDICINES, 2023, 11 (03)

← 1 2 3 4 5 →